Mild cognitive impairment and kidney disease: clinical aspects

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43918225" target="_blank" >RIV/00216208:11120/20:43918225 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1093/ndt/gfz051" target="_blank" >https://doi.org/10.1093/ndt/gfz051</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/ndt/gfz051" target="_blank" >10.1093/ndt/gfz051</a>

Result language
angličtina
Original language name
Mild cognitive impairment and kidney disease: clinical aspects
Original language description
We will try to summarize what we believe are the main open questions worth addressing with the aid of newer technologies: (i) Does the distinction between MCI-GP and MCI-CKD really exist or does MCI-CKD only represent an 'extreme' or 'accelerated' phenotype of MCI-GP? (ii) What is the contribution of accelerated aging and conventional cardiovascular risk factors to MCI-CKD? (iii) Do we have firm criteria for the diagnosis of MCICKD? (iv) What is the 'natural history' of MCI-CKD? (v) Can MCI-CKD be treated, prevented or even reversed? (vi) Can we properly assess the personal and socioeconomic burden of MCI-CKD?
Czech name
—
Czech description
—

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)